Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) has shared an announcement.
JCR Pharmaceuticals Co., Ltd., a Japan-based specialty drugmaker listed on the Tokyo Stock Exchange, develops and commercializes therapies for rare diseases and other difficult-to-treat conditions. Its portfolio spans approved treatments for growth disorders and several lysosomal storage and hematologic indications, and it is actively extending its reach into major overseas markets.
The company announced it has made partial corrections to its previously disclosed consolidated financial results for the six months ended September 30, 2025, after identifying descriptive errors in the original filing. While the underlying performance figures show a return to profitability and solid year-on-year growth in net sales, JCR stated that the corrections do not alter its dividend outlook or full-year earnings forecasts, signaling that operational and financial guidance remain intact for investors.
For the interim period, JCR reported net sales of ¥21,362 million, up 28.2% from a year earlier, with operating profit of ¥2,429 million and profit attributable to owners of the parent of ¥1,746 million, reversing the prior-year loss. The balance sheet remained stable with total assets of ¥108,956 million and an equity ratio of 44.4%, indicating a sound financial position alongside improving profitability.
The company maintained its plan to pay an annual dividend of ¥20 per share for FY2025, unchanged from the prior forecast, with an interim payment of ¥10 per share already set. It also reaffirmed its full-year guidance for the fiscal year ending March 31, 2026, projecting net sales of ¥37,800 million and profit attributable to owners of the parent of ¥3,000 million, underscoring confidence in its growth trajectory despite the need to amend reported figures.
The most recent analyst rating on (JP:4552) stock is a Buy with a Yen900.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceutical company focused on developing therapies that address rare diseases and other complex healthcare challenges. Building on a 50-year legacy in Japan, it markets treatments for growth disorders, lysosomal storage diseases, acute graft-versus-host disease, and renal anemia, while expanding its pipeline and commercial presence across the U.S., Europe, and Latin America.
The company leverages proprietary technologies to develop next-generation therapies for conditions such as MPS I, MPS II, and MPS III, aiming to improve outcomes in underserved patient populations worldwide. Its strategy emphasizes scientific innovation and global expansion, positioning JCR as a niche player in rare disease pharmaceuticals with a growing international footprint.
Average Trading Volume: 551,901
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen69.05B
Learn more about 4552 stock on TipRanks’ Stock Analysis page.